Skip to main content
ZYME $26.00 -0.15%
ZYME logo
ZYME · Zymeworks Inc.
Track ZYME — free
$26.00 -0.04 (-0.15%) Play latest call Q1 2026 earnings call transcript
Market Cap
$1.80B
Shares
69.03M
Volume · Nov 18 1.09M Avg daily vol (3M) 1.08M
All webcasts

Earnings call · FY2026 Q3

Zymeworks Inc. (ZYME) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $256.46M +828.7% YoY
Diluted EPS $2.28
Net income $173.70M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
Zymeworks raised 2026 revenue guidance to $337 million to $351 million and adjusted EBITDA guidance to $176 million to $190 million. Third-quarter revenue reached $256.5 million, primarily on a $250.0 million Ziihera milestone following first-line HER2-positive GEA approval.
10-Q report · filed Nov 9, 2026
Zymeworks reported net income of $84.5 million for the nine months ended September 30, 2026 and expects existing cash plus a $250.0 million Jazz milestone payment received in October 2026 to fund operations for at least the next twelve months.

The audio replay and transcript follow the call.

Forward guidance

3 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 9, 2026.

Metric Guided
Total revenue
2026
$337M – $351M
Adjusted EBITDA
2026
$176M – $190M
Annualized overhead and corporate costs to be eliminated
annualized
$13M – $15M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

License and Milestone Revenue$250.00M +890.1% YoY
Royalty and Other Revenue$4.91M +107.9% YoY
Viatris Collaboration Agreement Revenue$1.55M

Capital returned

Buybacks · derived
$11.99M
Full-screen source Call document